This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
Age range
6 Years – 17 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in Diastolic Blood Pressure at Up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in Pulse Rate at Up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in Height at up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in Weight at up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in Electrocardiogram (ECG) QRS Interval at up to 12 Weeks
Timeframe: Baseline and up to 12 weeks
Change From Baseline in ECG QTcF Interval at up to 12 Weeks
Timeframe: Baseline and up to 12 weeks